Although glucocorticoids are used for the treatment of as many as 50% of patients with inflammatory disorders such as rheumatoid arthritis, their use is associated with adverse effects. Beaulieu and Morand review the evidence that the glucocorticoid-induced leucine zipper protein (GILZ) might be a target that can be exploited to provide the beneficial anti-inflammatory effects of glucocorticoids without their negative metabolic repercussions.
- Elaine Beaulieu
- Eric F. Morand
